NCT01404949 2021-11-30
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
Clinical Trials
11 trialsNCT01470248 2021-02-17
Study of Arsenic Trioxide in Small Cell Lung Cancer
Emory University
Phase 2 Completed
NCT00469209 2020-09-24
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01791894 2018-06-08
ATO
Stanford University
Phase 1/2 Completed
NCT01428128 2017-12-13
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01184053 2017-06-14
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00582400 2016-02-19
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
The University of Texas Medical Branch, Galveston
Phase 2 Terminated
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00024258 2015-11-25
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00184054 2014-07-25
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
University of Southern California
Phase 2 Terminated
NCT00661544 2013-03-04
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed